FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Gut Healing Protocol

Recovery & Healingbeginner

80

协同作用

80
Share
肽类

2

平均每日mcg

1,500

级别

beginner

添加时间

May 17, 2026

概述

The Gut Healing Protocol combines BPC-157 administered orally with Larazotide (AT-1001) to address intestinal permeability and mucosal damage from the luminal side. BPC-157, originally isolated from human gastric juice, has a natural affinity for gastrointestinal tissue. When taken orally, it acts locally on the GI mucosa to promote healing of ulcerations, reduce inflammation, and restore tight junction integrity. Studies in animal models demonstrate its efficacy against NSAID-induced gut damage, inflammatory bowel conditions, and anastomosis healing. Larazotide acetate is an 8-amino-acid synthetic peptide that acts as a tight junction regulator. It works by inhibiting zonulin-mediated opening of intestinal tight junctions — the primary mechanism behind increased intestinal permeability ("leaky gut"). Larazotide completed Phase 3 clinical trials for celiac disease, where it demonstrated significant reduction in symptoms triggered by gluten exposure, confirming its mechanism of action in human subjects. Though not yet FDA-approved, it represents one of the most clinically validated peptides for gut barrier function. The combination works synergistically because BPC-157 addresses the underlying mucosal damage and inflammation driving gut dysfunction, while Larazotide provides immediate functional restoration of the tight junction barrier. BPC-157 heals the tissue; Larazotide prevents further permeability while healing occurs. This dual-mechanism approach addresses both the cause and consequence of intestinal hyperpermeability, making it suitable for individuals with IBS, post-infectious gut dysfunction, NSAID-induced enteropathy, or chronic intestinal inflammation. The oral route for both compounds makes this an accessible protocol requiring no injections.

给药方案

BPC-157

Every day· oral

了解更多关于BPC-157 →

500 mcg

每剂

Larazotide

3x daily· oral

了解更多关于Larazotide →

1,000 mcg

每剂

目标与证据

Gut healingLeaky gutIBSIntestinal repairMucosal health
证据等级:人体临床试验

警告

  • BPC-157 oral bioavailability data is limited. Larazotide (AT-1001) completed Phase 3 trials for celiac but is not yet FDA-approved.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。